|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, March 20, 2015 ) Dallas, TX -- The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years.
Squalamine (Squalamine lactate) is a first-in-class drug being developed by Ohr Pharmaceuticals as a novel eye drop solution treatment for wAMD. This small-molecule drug has a novel intracellular mechanism of action and can potently inhibit multiple protein growth factors involved in angiogenesis, including VEGF, PDGF, and bFGF.
Scope:
• Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Squalamine including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Squalamine for the top country from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain and UK.
Order a Purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=312785 . (This is a premium report priced at US$3495 for a single user License.)
Reasons to Buy:
• Understand and capitalize by identifying products that are most likely to ensure a robust return.
• Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration.
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
• Make more informed business decisions from insightful and in-depth analysis of Squalamine performance.
• Obtain sales forecast for Squalamine from 2013-2023 in top 6 countries (the US, France, Germany, Italy, Spain and UK).
Inquire for Discount at http://www.rnrmarketresearch.com/contacts/discount?rname=312785 .
Table of Contents:
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
2.1 Related Reports 12
3 Disease Overview 14
3.1 Macular Degeneration Overview 14
3.1.1 Etiology and Pathophysiology 16
3.1.2 Classification 20
3.1.3 Symptoms and Diagnosis 22
3.2 Macular Edema Overview 25
3.2.1 Etiology and Pathophysiology 26
3.2.2 Classification 29
3.2.3 Symptoms and Diagnosis 30
4 Disease Management 33
4.1 Diagnosis and Treatment Overview 33
4.1.1 Macular Edema Diagnosis 33
4.1.2 Macular Degeneration Diagnosis 33
4.1.3 Treatment Guidelines and Leading Prescribed Drugs 34
4.1.4 Clinical Practice 36
5 Competitive Assessment 50
5.1 Overview 50
6 Unmet Need and Opportunity 52
6.1 Overview 52
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research
Ritesh Tiwari
+ 1-888-391-5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
